Mutated in colorectal cancer (MCC) is a novel oncogene in B lymphocytes

详细信息    查看全文

• 作者：Shanique KE Edwards ; Jacqueline Baron ; Carissa R Moore…
• 关键词：MCC ; TRAF3 ; B lymphoma ; Multiple myeloma ; PARP1 ; PHB2
• 刊名：Journal of Hematology & Oncology
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：7
• 期：1
• 全文大小：2,015 KB
• 参考文献：1. Morton, LM, Wang, SS, Devesa, SS, Hartge, P, Weisenburger, DD, Linet, MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992-001. Blood 107: pp. 265-276 CrossRef
  2. Ruddon, R The Epidemiology of Human Cancer. In: Ruddon, RW eds. (2007) Book: Cancer Biology. Oxford University Press, New York, NY, USA, pp. 62-116
  3. Skibola, CF, Curry, JD, Nieters, A (2007) Genetic susceptibility to lymphoma. Haematologica 92: pp. 960-969 CrossRef
  4. Peled, JU, Kuang, FL, Iglesias-Ussel, MD, Roa, S, Kalis, SL, Goodman, MF, Scharff, MD (2008) The biochemistry of somatic hypermutation. Annu Rev Immunol 26: pp. 481-511 CrossRef
  5. Pasqualucci, L, Bhagat, G, Jankovic, M, Compagno, M, Smith, P, Muramatsu, M, Honjo, T, Morse, HC, Nussenzweig, MC, Dalla-Favera, R (2008) AID is required for germinal center-derived lymphomagenesis. Nat Genet 40: pp. 108-112 CrossRef
  6. Xie, P (2013) TRAF molecules in cell signaling and in human diseases. J Mol Signal 8: pp. 7 CrossRef
  7. Boucher, LM, Marengere, LE, Lu, Y, Thukral, S, Mak, TW (1997) Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily. Biochem Biophys Res Commun 233: pp. 592-600 CrossRef
  8. Nagel, I, Bug, S, Tonnies, H, Ammerpohl, O, Richter, J, Vater, I, Callet-Bauchu, E, Calasanz, MJ, Martinez-Climent, JA, Bastard, C, Salido, M, Schroers, E, Martin-Subero, JI, Gesk, S, Harder, L, Majid, A, Dyer, MJ, Siebert, R (2009) Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33). Leukemia 23: pp. 2153-2155 CrossRef
  9. Keats, JJ, Fonseca, R, Chesi, M, Schop, R, Baker, A, Chng, WJ, Wier, S, Tiedemann, R, Shi, CX, Sebag, M, Braggio, E, Henry, T, Zhu, YX, Fogle, H, Price-Troska, T, Ahmann, G, Mancini, C, Brents, LA, Kumar, S, Greipp, P, Dispenzieri, A, Bryant, B, Mulligan, G, Bruhn, L, Barrett, M, Valdez, R, Trent, J, Stewart, AK, Carpten, J, Bergsagel, PL (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12: pp. 131-144 CrossRef
  10. Annunziata, CM, Davis, RE, Demchenko, Y, Bellamy, W, Gabrea, A, Zhan, F, Lenz, G, Hanamura, I, Wright, G, Xiao, W, Dave, S, Hurt, EM, Tan, B, Zhao, H, Stephens, O, Santra, M, Williams, DR, Dang, L, Barlogie, B, Shaughnessy, JD, Kuehl, WM, Staudt, LM (2007) Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: pp. 115-130 CrossRef
  11. Braggio, E, Keats, JJ, Leleu, X, Wier, S, Jimenez-Zepeda, VH, Valdez, R, Schop, RF, Price-Troska, T, Henderson, K, Sacco, A, Azab, F, Greipp, P, Gertz, M, Hayman, S, Rajkumar, SV, Carpten, J, Chesi, M, Barrett, M, Stewart, AK, Dogan, A, Bergsagel, PL, Ghobrial, IM, Fonseca, R (2009) Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom’s macroglobulinemia. Cancer Res 69: pp. 3579-3588 CrossRef
  12. Xie, P, Stunz, LL, Larison, KD, Yang, B, Bishop, GA (2007) Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity 27: pp. 253-267 CrossRef
  13. Moore, CR, Liu, Y, Shao, CS, Covey, LR, Morse, HC, Xie, P (2012) Specific deletion of TRAF3 in B lymphocytes leads to B lymphoma development in mice. Leukemia 26: pp. 1122-1127 CrossRef
  14. Kinzler, KW, Nilbert, MC, Vogelstein, B,
• 刊物主题：Oncology; Hematology; Cancer Research;
• 出版者：BioMed Central
• ISSN：1756-8722

文摘

Background Identification of novel genetic risk factors is imperative for a better understanding of B lymphomagenesis and for the development of novel therapeutic strategies. TRAF3, a critical regulator of B cell survival, was recently recognized as a tumor suppressor gene in B lymphocytes. The present study aimed to identify novel oncogenes involved in malignant transformation of TRAF3-deficient B cells. Methods We used microarray analysis to identify genes differentially expressed in TRAF3??/sup> mouse splenic B lymphomas. We employed lentiviral vector-mediated knockdown or overexpression to manipulate gene expression in human multiple myeloma (MM) cell lines. We analyzed cell apoptosis and proliferation using flow cytometry, and performed biochemical studies to investigate signaling mechanisms. To delineate protein-protein interactions, we applied affinity purification followed by mass spectrometry-based sequencing. Results We identified mutated in colorectal cancer (MCC) as a gene strikingly up-regulated in TRAF3-deficient mouse B lymphomas and human MM cell lines. Aberrant up-regulation of MCC also occurs in a variety of primary human B cell malignancies, including non-Hodgkin lymphoma (NHL) and MM. In contrast, MCC expression was not detected in normal or premalignant TRAF3??/sup> B cells even after treatment with B cell stimuli, suggesting that aberrant up-regulation of MCC is specifically associated with malignant transformation of B cells. In elucidating the functional roles of MCC in malignant B cells, we found that lentiviral shRNA vector-mediated knockdown of MCC induced apoptosis and inhibited proliferation in human MM cells. Experiments of knockdown and overexpression of MCC allowed us to identify several downstream targets of MCC in human MM cells, including phospho-ERK, c-Myc, p27, cyclin B1, Mcl-1, caspases 8 and 3. Furthermore, we identified 365 proteins (including 326 novel MCC-interactors) in the MCC interactome, among which PARP1 and PHB2 were two hubs of MCC signaling pathways in human MM cells. Conclusions Our results indicate that in sharp contrast to its tumor suppressive role in colorectal cancer, MCC functions as an oncogene in B cells. Our findings suggest that MCC may serve as a diagnostic marker and therapeutic target in B cell malignancies, including NHL and MM.